Altimmune Inc (ALT)
$7.08
0.49 (6.47%)
ALT Stock Quote Delayed 30 Minutes
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
501.94M
PE Ratio
-4.27
EPS
-1.66
Volume (Avg. Vol.)
2.21M
Day's Range
$6.98 - $7.75
52-Week Range
$2.09 - $14.84
Dividend & Yield
N/A (N/A)
ALT Stock Predictions, Articles, and Altimmune Inc News
Why Is Altimmune (ALT) Stock Up 14% Today?
Altimmune stock is rising higher on Monday as ALT investors react to positive news from rival weight loss drugmaker Zealand Pharma.
Kerrisdale Capital Slams Altimmune (ALT) Stock in New Short Report
Kerrisdale Capital has released a short report, making clear why it is betting against ALT stock. Here's why Altimmune is likely in trouble.
Why Is Altimmune (ALT) Stock Up 43% Today?
Altimmune stock is rising higher on Friday with heavy trading of ALT shares after posting positive results form a clinical trial.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's the final day of trading this week and we're starting it with a breakdown of the biggest pre-market stock movers on Friday morning!
Why Is Altimmune (ALT) Stock Down 67% Today?
Altimmune (ALT) stock is losing value on Tuesday after the company released results from a Phase 2 clinical trial for obesity.
Altimune (ALT) Stock Plummets 33% Despite Positive Clinical Data
Altimune (ALT) stock is falling hard on Wednesday even after reporting positive results from a Phase 1b clinical trial this morning.
ALT Stock: One Analyst Still Thinks Altimmune Prices Could Hit $34
Some clinical trial results released by Altimmune have shareholders rushing to sell. But, one analyst sees plenty of upside for ALT stock.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning! We're taking a look at the biggest pre-market stock movers for Wednesday and that includes the winners and losers.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Get ready for another busy week of trading as we kick off Monday with a look at the biggest pre-market stock movers for today.
Altimmune Earnings: ALT Stock Rises 7% Despite Rough Q2 Results
Altimmune earnings from Tuesday evening have ALT stock higher despite the company reporting rough figures for second quarter of FY2020.
